Proactiveinvestors United Kingdom Arix Bioscience PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Arix Bioscience PLC RSS feed en Fri, 24 May 2019 20:13:59 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Arix Bioscience Plc - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201905100200PR_NEWS_UKDISCLO_0004/ Fri, 10 May 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201905100200PR_NEWS_UKDISCLO_0004/ <![CDATA[News - Arix Biosciences - venture capital firm flies under the market's radar ]]> https://www.proactiveinvestors.co.uk/companies/news/219791/arix-biosciences---venture-capital-firm-flies-under-the-market-s-radar-219791.html Arix is a venture capital company that invests in disruptive growth companies with the potential to significantly increase in worth as they progress through clinical trials and conduct financing rounds at higher valuations.

It aims to provide more than just capital when it invests. Arix will take a board seat and play an active role to support portfolio companies. It also brings to the party scientific and commercial experience to help navigate clinical and operational hurdles.

The firm’s PLC balance sheet enables it to take a longer-term view than non-listed peers that might have a set investment horizon. It can therefore provide investee businesses with the flexible, patient capital they require to grow.

Arix describes itself as being “unconstrained by institution, geography or stage of company development”. It therefore has the ability to source the best life science innovation without restriction.

Major investments

As at the end of last year, the gross portfolio was worth £175mln, up from £54mln. The net asset value, which is closely monitored by the market, was £270mln, or 200p a share, a rise of 48p from a year ago. Arix also revealed in its last results a net £70mln upward revaluation of the portfolio, primarily driven by investments core portfolio firms Autolus Therapeutics, LogicBio, and Harpoon Therapeutics.

Since the prelims were published at the end of March, the company has made further investments.

It increased its stake in investee company Aura Biosciences after backing the latter’s £31mln (US$40mln) Series D financing round. It did so by committing £3.4mln, taking its holding in the ocular oncology specialist to 7.7%.

It also agreed to invest another £3.8mln in Autolus Therapeutics PLC (NASDAQ:AUTL) as part of the latter’s IPO. The share purchase will keep Arix’s stake in Autolus at 7.5%, which is valued at £62.6mln.

Inflexion points

Looking ahead, investee companies have 26 clinical trials underway, with 19 expected to provide a clinical read-out. In other words, there are 19 potential value inflection points for Arix.

What the brokers say

“We continue to see Arix at current levels to be a good buying opportunity, with largely transparent valuations, trimmed cash opex and multiple catalysts ahead,” said Jefferies on April 29. Its price target is 270p.

“The shares trade at a around a 23% discount to our estimated 'core' NAV (portfolio carrying values + net cash) for Arix at 189p per  share, providing an attractive entry point to the stock, in our view,” said Stifel on April 10. “Arix has had a busy start to 2019, so far investing around £18m into its portfolio, continuing to put its capital work in the right areas.” Stifel reckons the stock is worth 285p. The share price as of May 7 was 153p.

]]>
Tue, 07 May 2019 06:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219791/arix-biosciences---venture-capital-firm-flies-under-the-market-s-radar-219791.html
<![CDATA[RNS press release - Arix Bioscience Plc - Issue of Ordinary Shares and Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201905010200PR_NEWS_UKDISCLO_0008/ Wed, 01 May 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201905010200PR_NEWS_UKDISCLO_0008/ <![CDATA[News - Arix Bioscience portfolio company Autolus Therapeutics raises US$109mln ]]> https://www.proactiveinvestors.co.uk/companies/news/218662/arix-bioscience-portfolio-company-autolus-therapeutics-raises-us109mln-218662.html Autolus Therapeutics PLC (NASDAQ:AUTL), a portfolio company of biotech investor Arix Bioscience PLC (LON:ARIX), has raised more than expected from its recent public offering.

Autolus, which is developing next-gen cancer immunotherapies, had originally set out to raise US$100.8mln through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

READ: Arix to invest another US$5mln in Autolus

But it ended up issuing 4.83mln ADS at the same price to raise US$109.0mln.

As part of the offering, Arix agreed to invest US$5mln, keeping its stake in Autolus at 7.5%, which is currently valued at US$94mln (£72mln).

Speaking last week, Arix chief executive Joe Anderson said: “Our investment in Autolus demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

]]>
Tue, 16 Apr 2019 08:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218662/arix-bioscience-portfolio-company-autolus-therapeutics-raises-us109mln-218662.html
<![CDATA[RNS press release - Arix Bioscience Plc - Autolus announces closing of public offering ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904160200PR_NEWS_UKDISCLO_0009/ Tue, 16 Apr 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904160200PR_NEWS_UKDISCLO_0009/ <![CDATA[News - Arix Bioscience to invest another US$5mln in Autolus ]]> https://www.proactiveinvestors.co.uk/companies/news/218403/arix-bioscience-to-invest-another-us5mln-in-autolus-218403.html Biotech investor Arix Bioscience PLC (LON:ARIX) has agreed to invest another £3.8mln (US$5.0mln) in Autolus Therapeutics PLC (NASDAQ:AUTL).

The share purchase will keep Arix’s stake in Autolus at 7.6%, which is valued at £62.6mln.

READ: Arix Bioscience confirms Autolus to launch proposed public offering

In total, Autolus is raising US$100.8mln from investors through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

“Our investment in Autolus today demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital,” said chief executive Joe Anderson.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

Arix backing its winners

“Arix first invested £10mln into Autolus's Series B round in March 2016,” noted analysts at US investment bank Stifel.

“Subsequent financing rounds, the Nasdaq IPO in June 2018 and now this latest equity offering, means Arix has invested £24.6mln so far into Autolus.

“That investment is now valued at £62.6m generating a decent return so far, but with the market effectively discounting the shares during the offering (shares sold at US$24 per ADS vs US$31 per ADS before the offer was announced), we would expect the shares to recover and provide greater value uplift for Arix.”

Arix shares were down 1.3% to 144.1p on Thursday morning.

--Adds analyst comment--

]]>
Thu, 11 Apr 2019 08:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218403/arix-bioscience-to-invest-another-us5mln-in-autolus-218403.html
<![CDATA[RNS press release - Arix Bioscience Plc - Autolus announces pricing of public offering ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904110200PR_NEWS_UKDISCLO_0010/ Thu, 11 Apr 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904110200PR_NEWS_UKDISCLO_0010/ <![CDATA[News - Arix Bioscience confirms Autolus to launch proposed public offering ]]> https://www.proactiveinvestors.co.uk/companies/news/218215/arix-bioscience-confirms-autolus-to-launch-proposed-public-offering-218215.html Biotech investor Arix Bioscience PLC (LON:ARIX) has confirmed that its investee company, Autolus Therapeutics PLC (NASDAQ:AUTL), has announced the launch of a proposed public offering in the United States.

The proposed maximum aggregate offering amount specified in the filing is 4mln American Depositary Shares (ADS), which does not include the underwriters’ option to purchase 600,000 additional ADS.

Each ADS represents one ordinary share. The final price per ADS in the offering will be determined following a book building process.

Arix shares were unchanged on Tuesday at 143p.

]]>
Tue, 09 Apr 2019 08:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218215/arix-bioscience-confirms-autolus-to-launch-proposed-public-offering-218215.html
<![CDATA[RNS press release - Arix Bioscience Plc - Autolus announces launch of proposed public offering ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904090200PR_NEWS_UKDISCLO_0010/ Tue, 09 Apr 2019 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904090200PR_NEWS_UKDISCLO_0010/ <![CDATA[News - Arix Bioscience increases stake in cutting-edge cancer company after backing its latest financing round ]]> https://www.proactiveinvestors.co.uk/companies/news/217723/arix-bioscience-increases-stake-in-cutting-edge-cancer-company-after-backing-its-latest-financing-round-217723.html Arix Bioscience PLC (LON:ARIX) said it had increased its stake in investee company Aura Biosciences after backing the latter’s £31mln (US$40mln) Series D financing round.

Arix committed £3.4mln, taking its holding in the ocular oncology specialist to 7.7%.

READ: Autolus Therapeutics presents promising leukaemia trial data at American Association for Cancer Research's annual meeting

Its total interest in the business rose to £8.5mln from £3.9mln, while the financing recognised a 33% uplift in the book value of Arix’s Series C investment in Aura.

The cash injection will fund Cambridge, Massachusetts-based Aura’s late-stage clinical development of its lead asset, light-activated AU-011, for the treatment of primary choroidal melanoma, a rare but aggressive eye cancer.

The ongoing phase Ib/II clinical trial has provided evidence of tumour control and the preservation of visual acuity (clarity of vision).

The phase III study is expected to get underway in the first half of next year. Arix chief executive Joe Anderson lauded the “significant clinical progress” made by Aura.

“We look forward to working alongside the world-class management team and new and existing investors to accelerate development of this potential new treatment,” he added.

Arix investment director, Mark Chin, will continue to serve on the Aura board.

After hours on Monday, data was presented from a phase I/II clinical trial being carried out by another Arix investee company, Autolus Therapeutics. The late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in Atlanta, Georgia, assessed the progress to date of a next-generation programmed T-cell therapy for patients with acute lymphoblastic B-cell leukaemia.

]]>
Tue, 02 Apr 2019 07:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217723/arix-bioscience-increases-stake-in-cutting-edge-cancer-company-after-backing-its-latest-financing-round-217723.html
<![CDATA[RNS press release - Arix Bioscience Plc - Aura completes $40 million Series D financing ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904020208PR_NEWS_UKDISCLO_0011/ Tue, 02 Apr 2019 07:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904020208PR_NEWS_UKDISCLO_0011/ <![CDATA[RNS press release - Arix Bioscience Plc - Autolus presents initial AUTO1 data at AACR ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904011310PR_NEWS_UKDISCLO_0145/ Mon, 01 Apr 2019 18:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201904011310PR_NEWS_UKDISCLO_0145/ <![CDATA[News - Arix Bioscience upbeat on prospects after making "encouraging progress" last year ]]> https://www.proactiveinvestors.co.uk/companies/news/217388/arix-bioscience-upbeat-on-prospects-after-making--encouraging-progress--last-year-217388.html Arix Bioscience PLC (LON:ARIX) shares rose on Thursday after the group said it is well positioned for further growth as it unveiled a heavy-hitting new independent director alongside full-year results.

The new appointment first: Corporate financier Mark Breuer, who spent the last two decades with JP Morgan, will join the audit committee when he officially takes on his non-executive role on April 25, replacing Meghan FitzGerald.

WATCH: Arix Bioscience acquires stake in novel firm developing sickle cell treatment

He joins a company that made significant headway last year, investing in the early-stage biotech and life sciences businesses.

Four Arix firms crossed the Rubicon to list on NASDAQ; while businesses it invested in raised £421mln (US$555mln).

Arix invests in disruptive growth companies with the potential to significantly increase in worth as they progress through clinical trials and conduct financing rounds at higher valuations.

As at the end of last year, the gross portfolio was worth £175mln, up from £54mln. The net asset value, which is closely monitored by the market, was £270mln, or 200p a share, a rise of 48p from a year ago. In late afternoon trading, Arix Bioscience shares were 3.5% higher 149p.

Arix also revealed a net £70mln upward revaluation of the portfolio, primarily driven by investments core portfolio firms Autolus Therapeutics, LogicBio, and Harpoon Therapeutics.

Strong young portfolio

Chief executive Joe Anderson said: “This performance is an early sign, I believe, of the potential in our business and the strength of the young portfolio we have built.”

A glance of the balance sheet reveals Arix had just over £91mln in un-invested cash or equivalents after raising £87mln in new capital a year ago.

In 2018, it ploughed £52mln into its portfolio, which now numbers 17 “innovative young companies”, while a further £16mln has been deployed so far this year. The company recently co-led a Series-B funding round for Imara, which is focused on sickle cell disease, and which brought in £48mln (US$63mln), as well as seeing investee company Harpoon list on NASDAQ, raising £61.5mln.

Looking ahead, investee companies have 26 clinical trials underway, with 19 expected to provide a clinical read-out. In other words, there are 19 potential value inflection points for Arix.

“We are well positioned for further growth and investment in 2019 and look forward to the year ahead with confidence and optimism,” said CEO Anderson.

 -- Adds share price --

]]>
Thu, 28 Mar 2019 07:48:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217388/arix-bioscience-upbeat-on-prospects-after-making--encouraging-progress--last-year-217388.html
<![CDATA[RNS press release - Arix Bioscience Plc - Annual Results for the year ended 31 December 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903280300PR_NEWS_UKDISCLO_0010/ Thu, 28 Mar 2019 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903280300PR_NEWS_UKDISCLO_0010/ <![CDATA[News - Arix Bioscience’s portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day ]]> https://www.proactiveinvestors.co.uk/companies/news/217221/arix-biosciences-portfolio-company-autolus-announces-positive-safety-data-for-auto3-ahead-of-inaugural-rd-day-217221.html Arix Bioscience PLC’s (LON:ARIX) portfolio company, Autolus Therapeutics, has announced positive updated safety and efficacy data for its AUTO3 leukaemia drug ahead of its inaugural R&D day in New York.

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease (MRD) negative complete responses (CR).

READ: Arix invests US$15mln in sickle cell treatment developer

A patient who tests MRD negative has less than one cancer cell per million bone marrow cells, meaning the disease is all but gone.

Ongoing MRD negative CR remissions were noted in four of the six patients, with duration of up to 10 months as of February 2019, the date of latest data follow-up.

Nasdaq-listed Autolus added that AUTO3 continues to be generally well tolerated with none of the patients needing critical care for cytokine release syndrome – a condition that occurs with some forms of immunotherapy.

The Phase II portion of the study remains on track to begin in the second half of this year.

R&D day later today

Autolus made the announcement ahead of its inaugural R&D day in New York which is due to get underway later today.

Chairman and chief executive Christian Itin will be one of those giving a presentation, as will several other execs.

“We are pleased to be hosting our inaugural R&D day, providing a unique opportunity to present an in-depth overview of our differentiated technology, multiple programs, market opportunities and the significant pipeline progress we have achieved, to date,” said Autolus boss Itin.

“We expect to report data on all of our active clinical programs at key medical conferences during 2019. Additionally, over the coming months, we expect to move two programs into registrational trials and to progress our next generation programs toward the clinic.”

Shares in Arix, which has results out on Thursday, edged 1% higher to 145.5p in late-morning trading on Tuesday.

]]>
Tue, 26 Mar 2019 11:40:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217221/arix-biosciences-portfolio-company-autolus-announces-positive-safety-data-for-auto3-ahead-of-inaugural-rd-day-217221.html
<![CDATA[RNS press release - Arix Bioscience Plc - Autolus hosts R&D day and provides update on AUTO3 ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903260617PR_NEWS_UKDISCLO_0044/ Tue, 26 Mar 2019 10:17:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903260617PR_NEWS_UKDISCLO_0044/ <![CDATA[RNS press release - Arix Bioscience Plc - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903200823PR_NEWS_UKDISCLO_0076/ Wed, 20 Mar 2019 12:23:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903200823PR_NEWS_UKDISCLO_0076/ <![CDATA[Media files - Arix Bioscience acquires stake in novel firm developing sickle cell treatment ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12642/arix-bioscience-acquires-stake-in-novel-firm-developing-sickle-cell-treatment-12642.html Tue, 19 Mar 2019 13:39:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/12642/arix-bioscience-acquires-stake-in-novel-firm-developing-sickle-cell-treatment-12642.html <![CDATA[News - Arix Bioscience invests US$15mln in sickle cell treatment developer Imara ]]> https://www.proactiveinvestors.co.uk/companies/news/216623/arix-bioscience-invests-us15mln-in-sickle-cell-treatment-developer-imara-216623.html Arix Bioscience PLC (LON:ARIX) said it has invested US$15mln (£11.3mln) in Imara, a company developing treatments for sickle cell disease.

The health and life science investor said the sum would give it a 10% stake in the company and expand the breadth of its portfolio.

READ: Arix Bioscience appoints Joe Anderson CEO in boardroom reshuffle

Based in Massachusetts, Imara is developing a treatment designed to inhibit the underlying causes of sickle cell disease, a group of inherited conditions that cause red blood cells to be sickle-shaped meaning they do not survive as long as healthy cells and can become stuck in blood vessels.

This can lead to symptoms such as anaemia when blood cells can’t carry enough oxygen around the body, as well as an increased risk of serious infections and painful episodes called sickle cell crises which can last up to a week.

The treatment, known as IMR-687, has already successfully completed a phase 1 study in healthy volunteers and is currently in a global phase 2a study using adult sickle cell patients.

Joe Anderson, chief executive of Arix, said it would be working with Imara and its co-investors to help “accelerate the development” of the company.

“Sickle cell disease affects a large and growing population across the world and is devastating for both patients and families. Imara is led by an exceptional team developing a novel, compelling approach to treating this difficult disease.”

In early trading Monday, Arix shares were down 1.7% at 145p.

]]>
Mon, 18 Mar 2019 08:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216623/arix-bioscience-invests-us15mln-in-sickle-cell-treatment-developer-imara-216623.html
<![CDATA[RNS press release - Arix Bioscience Plc - Arix co-leads $63m Series B investment round for Imara ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903180300PR_NEWS_UKDISCLO_0006/ Mon, 18 Mar 2019 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201903180300PR_NEWS_UKDISCLO_0006/ <![CDATA[RNS press release - Arix Bioscience Plc - Autolus announces updated results from CARPALL trial ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902190712PR_NEWS_UKDISCLO_0062/ Tue, 19 Feb 2019 12:12:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902190712PR_NEWS_UKDISCLO_0062/ <![CDATA[News - Arix Bioscience appoints Joe Anderson CEO in boardroom reshuffle ]]> https://www.proactiveinvestors.co.uk/companies/news/214846/arix-bioscience-appoints-joe-anderson-ceo-in-boardroom-reshuffle-214846.html Arix Bioscience PLC (LON:ARIX) said chief investment officer Joe Anderson has been re-appointed chief executive.

Executive chairman Jonathan Peacock will stay in his role, but in a non-executive capacity at the life sciences investment company, while biotechnology entrepreneur Sir Christopher Evans is retiring as a director after a three-year term. Evans will continue as a consultant.

“Our core value is in the portfolio of companies we have built, and continue to build,” said Anderson.

READ: Arix Bioscience quids in after Harpoon completes flotation on NASDAQ

“We have seen rapid growth in our net asset value and we are confident that this will convert into value for shareholders, whilst the pipeline of new opportunities remains strong.

“I appreciate the confidence placed in me by the Board to lead this exceptional organisation as we continue to deliver on our strategy.”

In early afternoon trading, Arix shares were at 161p.

Ken Rumph, of broker Jefferies, said shareholders may question the process of reappointing Anderson after seeking outside candidates for the role.

However, the analyst said they will “welcome the outcome in cost and clarity terms”.

“While the process wasn't smooth, the reality is that the strategy hasn't changed, and a well-regarded CEO is restored to a more focused leadership,” he explained.

“We don't characterise this as a boardroom power struggle, but the changes address criticism over the top-heavy executive team and costs, with an outcome of a clear leadership structure and the move of Sir Chris, a high profile but polarising figure, to a more arms-length role.”

Autolus presents more data

In a later statement, Arix Bioscience also noted that its portfolio company, Autolus Therapeutics PLC (NASDAQ:AUTL) has presented updated data from the ongoing Phase 1 CARPALL trial of AUTO1 in a poster presentation at the European Hematology Association 1st European CAR T Cell Meeting held in Paris, France, February 14-16, 2019.

In an announcement on its investor website, Autolus said that Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH) and NIHR Research Professor of Transplantation Immunology at University College London (UCL) Great Ormond Street Institute of Child Health, said: "AUTO1 combines a high molecular CR rate with excellent persistence and a good safety profile in pediatric acute B cell leukemia patients.”

 -- Adds Autolus update, updates share price --

]]>
Tue, 19 Feb 2019 07:20:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214846/arix-bioscience-appoints-joe-anderson-ceo-in-boardroom-reshuffle-214846.html
<![CDATA[RNS press release - Arix Bioscience Plc - Management and Board changes ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902190200PR_NEWS_UKDISCLO_0009/ Tue, 19 Feb 2019 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902190200PR_NEWS_UKDISCLO_0009/ <![CDATA[News - Arix Bioscience quids in after Harpoon completes flotation on NASDAQ ]]> https://www.proactiveinvestors.co.uk/companies/news/214616/arix-bioscience-quids-in-after-harpoon-completes-flotation-on-nasdaq-214616.html Global healthcare and life sciences company Arix Bioscience PLC (LON:ARIX) said Harpoon Therapeutics, one of its portfolio companies, has completed its flotation on NASDAQ.

Harpoon, a clinical-stage immunotherapy company developing a novel class of T cell engagers, completed an initial public offering (IPO) of 5.4mln shares at US$14 a shot, raising US$75.6mln.

READ: Arix Bioscience boost after Harpoon NASDAQ float

Arix retains a stake of 12.1% in Harpoon, which was valued at £31.3mln at the close of business on 13 February 2019, representing a gain of £12.1mln on total cash invested in Harpoon by Arix.

Arix has a market capitalisation of around £220mln.

]]>
Thu, 14 Feb 2019 07:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214616/arix-bioscience-quids-in-after-harpoon-completes-flotation-on-nasdaq-214616.html
<![CDATA[RNS press release - Arix Bioscience Plc - Harpoon closes initial public offering ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902140200PR_NEWS_UKDISCLO_0009/ Thu, 14 Feb 2019 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902140200PR_NEWS_UKDISCLO_0009/ <![CDATA[News - Arix Bioscience boost after Harpoon NASDAQ float ]]> https://www.proactiveinvestors.co.uk/companies/news/214237/arix-bioscience-boost-after-harpoon-nasdaq-float-214237.html Healthcare investment company Arix Bioscience Plc (LON:ARIX) said a fourth portfolio company is listing on the stock market, increasing the valuation of its shareholding.

Harpoon Therapeutics, which is developing T-cell immunotherapies for cancer, is raising £58.4mln from the NASDAQ float.

READ: Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

Arix has followed its money by ploughing £4.6mln into the IPO. This takes its stake to 12.1%, which is worth £31.3mln, which includes a boost to the fair value of the original holding of £6.2mln.

“Coupled with its scientific expertise and strong management team, we believe Harpoon is well-positioned to play a significant role in immuno-oncology,” said chief investment officer Joe Anderson.

“As early investors in Harpoon, we are excited to see the potential of the company continue to grow.”

]]>
Fri, 08 Feb 2019 07:39:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214237/arix-bioscience-boost-after-harpoon-nasdaq-float-214237.html
<![CDATA[RNS press release - Arix Bioscience Plc - Harpoon prices Nasdaq IPO ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902080209PR_NEWS_UKDISCLO_0009/ Fri, 08 Feb 2019 07:09:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902080209PR_NEWS_UKDISCLO_0009/ <![CDATA[RNS press release - Arix Bioscience Plc - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902010538PR_NEWS_UKDISCLO_0060/ Fri, 01 Feb 2019 10:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201902010538PR_NEWS_UKDISCLO_0060/ <![CDATA[News - Arix Bioscience says Harpoon Therapeutics’ IPO pricing range would hike holding value by £4.2mln-£7.9mln ]]> https://www.proactiveinvestors.co.uk/companies/news/213536/arix-bioscience-says-harpoon-therapeutics-ipo-pricing-range-would-hike-holding-value-by-42mln-79mln-213536.html Arix Bioscience PLC (LON:ARIX) noted that further details of proposals by Harpoon Therapeutics Inc. for an underwritten US initial public offering would represent a £4.2mln-£7.9mln increase in the value of its current shareholding in Harpoon.

The LSE main market-listed global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding.

READ: Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

The UK firm pointed out the figures are based on Harpoon’s amended registration statement, filed with the US Securities and Exchange, which discloses an expected pricing range for the proposed offering of US$13.00–US$15.00 per share.

It noted that the proposed maximum aggregate offering amount specified in the filing is US$93.15mln, which assumes that the public offering price is at the top of the expected pricing range and includes the option that is proposed to be granted to the underwriters to purchase additional shares of common stock.

Arix also said it has indicated an interest in purchasing shares of common stock in the offering, subject to agreement with the underwriters.

]]>
Tue, 29 Jan 2019 14:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213536/arix-bioscience-says-harpoon-therapeutics-ipo-pricing-range-would-hike-holding-value-by-42mln-79mln-213536.html
<![CDATA[RNS press release - Arix Bioscience Plc - Update on Harpoon proposed IPO in the United States ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201901290925PR_NEWS_UKDISCLO_0074/ Tue, 29 Jan 2019 14:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201901290925PR_NEWS_UKDISCLO_0074/ <![CDATA[RNS press release - Arix Bioscience Plc - Issue of Ordinary Shares and Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201901030200PR_NEWS_UKDISCLO_0009/ Thu, 03 Jan 2019 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201901030200PR_NEWS_UKDISCLO_0009/ <![CDATA[News - Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO ]]> https://www.proactiveinvestors.co.uk/companies/news/211768/arix-bioscience-portfolio-firm-harpoon-therapeutics-plans-us-ipo-211768.html Harpoon Therapeutics Inc., a portfolio company of Arix Bioscience PLC (LON:ARIX) is planning to float in the US.

Arix said Harpoon has filed a registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering.

READ: Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy

Harpoon is a clinical-stage immuno-oncology company developing T cells to fight cancer and other diseases.

]]>
Fri, 28 Dec 2018 08:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211768/arix-bioscience-portfolio-firm-harpoon-therapeutics-plans-us-ipo-211768.html
<![CDATA[RNS press release - Arix Bioscience Plc - Harpoon announces proposed public offering in the US ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201812280200PR_NEWS_UKDISCLO_0011/ Fri, 28 Dec 2018 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201812280200PR_NEWS_UKDISCLO_0011/ <![CDATA[RNS press release - Arix Bioscience Plc - Arix appoints Dr Christian Schetter as EIR ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201812110200PR_NEWS_UKDISCLO_0013/ Tue, 11 Dec 2018 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201812110200PR_NEWS_UKDISCLO_0013/ <![CDATA[News - Arix Bioscience sees multiple advancements across portfolio ]]> https://www.proactiveinvestors.co.uk/companies/news/210397/arix-bioscience-sees-multiple-advancements-across-portfolio-210397.html Healthcare and life science investment firm Arix Bioscience Plc (LON:ARIX) has seen a number of positive developments across its portfolio, ranging from successful clinical trials to stock market floats.

New trials at Autolus

In early December, one of Arix’s portfolio companies Autolus Therapeutics PLC (NASDAQ:AUTL), dosed the first patient in a Phase 1/2 clinical trial of its AUTO4 therapy for relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL).

PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin when T-cells, white blood cells that fight infection, become abnormal.

READ: Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy

The first phase of the trial is expected to enrol around 25 patients and evaluate up to three dose levels of the AUTO4 therapy, beginning with a low dose of 25mln AUTO4 cells in cohorts of three to six patients.

If no toxicities are observed, the doses will then escalate to 75mln and 225mln until a recommended dose has been identified, after which up to 30 patients will be enrolled in Phase 2.

Two of AUTO4’s sister treatments, AUTO5 targeting TRBC2-positive lymphoma and AUTO3 targeting paediatric acute lymphoblastic leukaemia and diffuse large B cell lymphoma, had preclinical data and Phase 1/2 trial clinical data presented at the annual meeting of the American Society of Hematology (ASH) on 2 December.

Trial success for Pharmaxis

Meanwhile, one of the firm’s Australia-based investments, Pharmaxis (ASX:PXS), saw success in November with a two-part Phase 1 clinical study of its LOXL2 inhibitor.

LOXL2 is designed to treat fibrotic diseases such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis.

READ: Arix Biosciences hails phase I success of investee company Pharmaxis

The study revealed that the drug was safe and there were no adverse reactions, with its pharmacokinetic profile showing “the expected dose related-increases in exposure”.

Repeating the positive results seen in a similar trial for its first inhibitor compound, “excellent drug-like properties [were] demonstrated”, Pharmaxis said.

Arix is a cornerstone investor in the ASX life sciences group and led August’s £13.4mln financing round.

Positive results eyed by Aura

The round of positive results also extended to another Arix investee Aura Biosciences, in which it holds a 6.6% stake.

Aura is developing AU-011, an injection which made up of viral nanoparticles which latch onto and, once activated by an ophthalmic laser, kill cancer cells in the back of the eye.

READ: Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial

A Phase Ib/II clinical trial of AU-011 in October demonstrated that “light-activated AU-011 continues to be well-tolerated, including with multiple administrations, has evidence of tumour control and preservation of visual acuity”, according to the trial’s principal investigator Brian Marr.

Nasdaq float for LogicBio

In October, the group saw a significant uplift in its investment in clinical genome editing company LogicBio (NASDAQ:LOGC), which floated on the Nasdaq exchange in an initial public offering that valued the firm at over US$200mln and raised proceeds of US$80.5mln.

READ: Arix Biosciences boost after investee company floats on NASDAQ

For Arix, which holds a 12.9% stake in the firm, the float took the value of its holding to US$30mln, US$16mln more than it ploughed into the business.

With shares trading at around 176.5p, Arix carries a market cap of £231.2mln.

]]>
Mon, 03 Dec 2018 08:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210397/arix-bioscience-sees-multiple-advancements-across-portfolio-210397.html
<![CDATA[News - Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy ]]> https://www.proactiveinvestors.co.uk/companies/news/210361/arix-biosciences-portfolio-firm-autolus-doses-first-patient-in-clinical-trial-of-auto4-t-cell-lymphoma-therapy-210361.html Arix Bioscience Plc’s (LON:ARIX) portfolio company, Autolus Therapeutics PLC (NASDAQ:AUTL), has dosed the first patient in a Phase 1/2 clinical trial of its AUTO4 therapy for relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL).

PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin when T-cells, white blood cells that fight infection, become abnormal.

READ: Arix Biosciences hails phase I success of investee company Pharmaxis

The first phase of the trial is expected to enrol around 25 patients and evaluate up to three dose levels of the AUTO4 therapy, beginning with a low dose of 25mln AUTO4 cells in cohorts of three to six patients.

If no toxicities are observed, the doses will then escalate to 75mln and 225mln until a recommended dose has been identified, after which up to 30 patients will be enrolled in Phase 2.

Arix also said that data from Autolus’ preclinical programme for AUTO5, a sister to AUTO4 targeting TRBC2-positive lymphoma, was presented at the annual meeting of the American Society of Hematology (ASH) on 2 December.

In a separate announcement, the company added that clinical data from Phase 1/2 trials of Autolus’ AUTO3 treatment had also been presented at the ASH conference.

AUTO3 is a treatment targeting paediatric acute lymphoblastic leukemia, the single most common form of cancer in children, and diffuse large B cell lymphoma, a cancer that affects B-cells which produce antibodies.

The news follows early-stage clinical trial successes from another of the firm’s company’s, Australian firm Pharmaxis (ASX:PXS) in November.

A two-part phase I clinical study revealed Pharmaxis’ drug was safe and there were no adverse reactions.

]]>
Mon, 03 Dec 2018 07:51:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210361/arix-biosciences-portfolio-firm-autolus-doses-first-patient-in-clinical-trial-of-auto4-t-cell-lymphoma-therapy-210361.html
<![CDATA[RNS press release - Arix Bioscience Plc - Autolus presents initial AUTO3 clinical data at ASH ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201812030200PR_NEWS_UKDISCLO_0011/ Mon, 03 Dec 2018 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201812030200PR_NEWS_UKDISCLO_0011/ <![CDATA[News - Arix Biosciences hails phase I success of investee company Pharmaxis ]]> https://www.proactiveinvestors.co.uk/companies/news/209250/arix-biosciences-hails-phase-i-success-of-investee-company-pharmaxis-209250.html Arix Biosciences PLC (LON:ARIX) has hailed the early-stage clinical trial success of an Australia-based pharma company in which it has a significant stake.

Pharmaxis (ASX:PXS) is developing what’s called a LOXL2 inhibitor to treat fibrotic diseases such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis.

WATCH: Aura Biosciences reports positive clinical data on its eye cancer treatment therapy

The two-part phase I clinical study revealed Pharmaxis’ drug was safe and there were no adverse reactions.

The pharmacokinetic profile of the treatment “showed the expected dose related-increases in exposure”, the data revealed. Pharmacokinetics relates to the way the drug is absorbed and distributed.

Repeating the positive results seen in a similar trial for its first inhibitor compound, “excellent drug-like properties [were] demonstrated”, Pharmaxis said.

Arix is a cornerstone investor in the ASX life sciences group and led August’s £13.4mln financing round.

Pharmaxis will host an investor research briefing on Tuesday, 20 November from 10 am to 12.00 noon, (Australian eastern daylight time).

]]>
Thu, 15 Nov 2018 07:28:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209250/arix-biosciences-hails-phase-i-success-of-investee-company-pharmaxis-209250.html
<![CDATA[RNS press release - Arix Bioscience Plc - Positive Phase 1 clinical trial results ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201811150200PR_NEWS_UKDISCLO_0009/ Thu, 15 Nov 2018 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201811150200PR_NEWS_UKDISCLO_0009/ <![CDATA[News - Arix Bioscience participates in US$70mln Harpoon Series C investment round ]]> https://www.proactiveinvestors.co.uk/companies/news/208982/arix-bioscience-participates-in-us70mln-harpoon-series-c-investment-round-208982.html Arix Bioscience Plc (LON:ARIX) has invested another US$8.0mln (£6.1mln) in the US$70mln Series C financing of cancer immunotherapy specialist Harpoon Therapeutics.

The funding round resulted in resulted in a write-up of Arix’s initial investment in Harpoon to £14.1mln, a £4.7mln uplift to the most recent valuation of £9.4mln.

Including the £6.1mln Series C investment, the value of Arix’s 11.3% stake in Harpoon has increased to £20.2mln.

WATCH: Arix investee company Aura reports positive clinical data

Arix investment director Mark Chin will continue to serve on Harpoon’s board of directors.

Harpoon will use the proceeds from the financing to support further advancement of its immunotherapy programs based on its TriTAC and ProTriTAC platforms, which are designed to harness the natural power of the body’s immune system to fight cancer and other diseases.

Its lead candidate, HPN224, is currently in phase I clinical trial as a potential treatment for prostate cancer.

Harpoon also plans to initiate a phase I clinical trials in for HPN536 for the treatment of mesothelin-expressing tumours, and HPN217 for the treatment of multiple myeloma, in 2019.

On top of that, Harpoon expects to advance its first ProTriTAC product candidate into IND-enabling studies in 2019.

]]>
Mon, 12 Nov 2018 07:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208982/arix-bioscience-participates-in-us70mln-harpoon-series-c-investment-round-208982.html
<![CDATA[RNS press release - Arix Bioscience Plc - Arix invests in $70m Harpoon Series C investment round ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201811120200PR_NEWS_UKDISCLO_0008/ Mon, 12 Nov 2018 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201811120200PR_NEWS_UKDISCLO_0008/ <![CDATA[Media files - Aura Biosciences reports positive clinical data on its eye cancer treatment therapy ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11122/aura-biosciences-reports-positive-clinical-data-on-its-eye-cancer-treatment-therapy-11122.html Tue, 06 Nov 2018 15:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11122/aura-biosciences-reports-positive-clinical-data-on-its-eye-cancer-treatment-therapy-11122.html <![CDATA[RNS press release - Arix Bioscience Plc - Autolus Therapeutics to Present New Data at the ASH ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201811020733PR_NEWS_UKDISCLO_0067/ Fri, 02 Nov 2018 11:33:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201811020733PR_NEWS_UKDISCLO_0067/ <![CDATA[Media files - Arix Bioscience Plc portfolio company Iterum Therapeutics updates on its antibiotic drug ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11065/arix-bioscience-plc-portfolio-company-iterum-therapeutics-updates-on-its-antibiotic-drug-11065.html Wed, 31 Oct 2018 11:26:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11065/arix-bioscience-plc-portfolio-company-iterum-therapeutics-updates-on-its-antibiotic-drug-11065.html <![CDATA[News - Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial ]]> https://www.proactiveinvestors.co.uk/companies/news/208150/arix-biosciences-investee-company-aura-biosciences-announces-positive-data-from-mid-stage-eye-cancer-trial-208150.html Arix Bioscience Plc’s (LON:ARIX) investee company Aura Biosciences has reported positive results from the phase Ib/II clinical trial of its AU-011 eye cancer injection.

AU-011 is made up of viral nanoparticles which latch onto and, once activated by an ophthalmic laser, kill cancer cells in the back of the eye.

READ: Arix boosted by LogicBio's Nasdaq IPO

Importantly, they do this without damaging the surrounding tissue, preserving patients’ vision.

Brian Marr, the trial’s principal investigator, said: “These 12-month data demonstrate that light-activated AU-011 continues to be well-tolerated, including with multiple administrations, has evidence of tumour control and preservation of visual acuity”

Arix chief investment officer Joe Anderson added: “We believe that this minimally invasive, non-radiation-based treatment option, has the potential to offer a new treatment option for patients.”

“We continue to support Aura as the company progresses towards a pivotal phase III study.”

Arix, which has a 6.6% stake in Aura, saw its shares drop 4.1% to 162.6p in late-afternoon trading.

]]>
Tue, 30 Oct 2018 14:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208150/arix-biosciences-investee-company-aura-biosciences-announces-positive-data-from-mid-stage-eye-cancer-trial-208150.html
<![CDATA[RNS press release - Arix Bioscience Plc - Aura Biosciences reports positive Phase 1b/2 data ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201810301011PR_NEWS_UKDISCLO_0088/ Tue, 30 Oct 2018 14:11:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201810301011PR_NEWS_UKDISCLO_0088/ <![CDATA[News - Arix Biosciences boost after investee company floats on NASDAQ ]]> https://www.proactiveinvestors.co.uk/companies/news/207721/arix-biosciences-boost-after-investee-company-floats-on-nasdaq-207721.html Arix Biosciences PLC (LON:ARIX) has seen a significant uplift in the value of its investment in a pre-clinical genome editing company, which recently made its stock market debut on NASDAQ.

The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio (NASDAQ:LOGC), worth US$30mln, which is US$16mln more than Arix ploughed into the business.

READ: Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq

The IPO, meanwhile, brought in gross proceeds of US$80.5mln and valued LogicBio at just over US$200mln at US$10 a share.

Founded four years ago and based in Cambridge, Massachusetts, the research and development group has licensed technology from Stanford and Texas universities that allows the insertion of corrective genes to the human genome.

It’s hoped the advance will allow LogicBio to create treatments for rare diseases with the company focusing initially on liver disorders in children.

]]>
Wed, 24 Oct 2018 07:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207721/arix-biosciences-boost-after-investee-company-floats-on-nasdaq-207721.html
<![CDATA[RNS press release - Arix Bioscience Plc - LogicBio announces closing of initial public offering ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201810240200PR_NEWS_UKDISCLO_0013/ Wed, 24 Oct 2018 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201810240200PR_NEWS_UKDISCLO_0013/ <![CDATA[News - Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq ]]> https://www.proactiveinvestors.co.uk/companies/news/207448/arix-bioscience-pours-another-54mln-into-logicbio-as-investee-company-lists-on-nasdaq-207448.html Life sciences investor Arix Bioscience Plc (LON:ARIX) has poured another £5.4mln into LogicBio Therapeutics as part of the gene editing specialist’s IPO in New York today (Friday).

The investment will keep Arix’s stake in LogicBio at 13.5%.

LogicBio, which is developing a genome editing platform called GeneRide, is selling shares at US$10 apiece as part of the flotation, valuing it at around £170mln (US$220mln) post-money.

IN-DEPTH: Arix lines up opportunities as life sciences bound ahead

That means Arix’s current investment, previously valued at just shy of £5mln, is now worth £17.5mln.

Including the additional investment announced on Friday, Arix’s total stake in LogicBio now sits at £22.9mln.

“Gene therapy offers great promise for tackling rare diseases and the science is advancing rapidly,” said Arix chief investment officer Joe Anderson.

“Genetic disease in early childhood presents a particular set of challenges, which we believe LogicBio has the potential to address with its GeneRide technology. We continue to work with the company as it advances towards the clinic with potential breakthrough treatments for patients.”

LogicBio’s is the third public listing of an Arix company – after Autolus and Iterum – and comes just three years after LogicBio's inception.

Arix shares were unmoved at 172.1p in early deals on Friday.

]]>
Fri, 19 Oct 2018 08:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207448/arix-bioscience-pours-another-54mln-into-logicbio-as-investee-company-lists-on-nasdaq-207448.html
<![CDATA[RNS press release - Arix Bioscience Plc - LogicBio prices Nasdaq IPO ]]> https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201810190200PR_NEWS_UKDISCLO_0010/ Fri, 19 Oct 2018 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/rns/15640/PRNRNS_201810190200PR_NEWS_UKDISCLO_0010/